OncoCyte Co. (NASDAQ:OCX) Short Interest Down 36.4% in July

OncoCyte Co. (NASDAQ:OCX) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 291,300 shares, a decrease of 36.4% from the June 30th total of 458,300 shares. Based on an average daily volume of 39,700 shares, the days-to-cover ratio is currently 7.3 days. Currently, 2.5% of the shares of the company are short sold.

Analyst Ratings Changes

OCX has been the subject of a number of research reports. Stephens reaffirmed an “equal weight” rating and issued a $4.00 target price on shares of OncoCyte in a report on Wednesday, April 17th. StockNews.com assumed coverage on OncoCyte in a research note on Tuesday. They issued a “sell” rating on the stock. Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a report on Monday, April 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research report on Thursday, May 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $4.06.

OncoCyte Price Performance

NASDAQ OCX traded down $0.04 during trading hours on Friday, reaching $3.32. The company’s stock had a trading volume of 312 shares, compared to its average volume of 43,905. The company’s 50-day moving average is $2.90 and its two-hundred day moving average is $2.93. OncoCyte has a fifty-two week low of $2.08 and a fifty-two week high of $4.34.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. The company had revenue of $0.18 million for the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%. As a group, research analysts forecast that OncoCyte will post -2.58 earnings per share for the current fiscal year.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.